Abstracts Archive - Page 540 of 1683 - ATC Abstracts

2020 American Transplant Congress
The Clinical Significance of C1q+ Antibodies in Pediatric Kidney Transplant Recipients
N. Hayde¹, S. Solomon², A. Colovai¹
¹Montefiore Medical Center, Bronx, NY, ²Westchester Medical Center, Valhalla, NY
*Purpose: To evaluate the impact of denovo DSA (C1q+ vs C1q-) on graft outcomes in pediatric kidney transplant recipients.*Methods: Children transplanted between 2009 and 2016…
2020 American Transplant Congress
Factors Associated with Hepatocellular Carcinoma Understaging for Liver Transplantation, and Variation in Understaging by Transplant Center
N. Mahmud¹, M. Hoteit¹, D. Goldberg²
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Miami, Miami, FL
*Purpose: Hepatocellular carcinoma (HCC) may be cured by liver transplantation (LT) in selected patients, though recurrence rates remain high. Patients who are reported as within…
2020 American Transplant Congress
Effects of Mandatory 6-Month Waiting Time Policy on Post-Transplant Outcomes and Explant Pathology in Liver Transplant Patients with Hepatocellular Carcinoma
S. Nagai, T. Kitajima, S. Yeddula, R. Salgia, M. Abouljoud, D. Moonka
Henry Ford Hospital, Detroit, MI
*Purpose: In the United States, current allocation policy mandates a 6-month waiting period before exception scores are granted to liver transplant (LT) candidates with hepatocellular…
2020 American Transplant Congress
Potential Benefits of Y-90 Radiation Microspheres for Bridging Liver Candidates with Hepatocellular Carcinoma to Liver Transplant
S. Pelletier¹, J. Durden², S. Shan², P. Vargas³, N. Goldaracena¹
¹University of Virginia Health System, Charlottesville, VA, ²School of Medicine, University of Virginia Health System, Charlottesville, VA, ³Department of Surgery, University of Virginia Health System, Charlottesville, VA
*Purpose: In October 2015, the UNOS policy for hepatocellular carcinoma (HCC) exception scores was changed to modify the maximum exception value and prolong the time…
2020 American Transplant Congress
Living Donor Liver Transplantation for Unresectable Liver Confined Colorectal Liver Metastases: A North American Experience
L. I. Ruffolo, K. Dokus, M. Larye, J. Errigo, J. Bhoely, R. Dunne, M. Levstik, B. Al-Jadaibi, K. Tomiyama, R. Hernandez-Alejandro
Surgery, University of Rochester Medical Center, Rochester, NY
*Purpose: Colorectal cancer is the third leading cause of cancer related death, and 50% of patients will either present with synchronous or develop colorectal liver…
2020 American Transplant Congress
The Addition of Splenectomy to Simultaneous Liver Kidney Transplantation Improves Class II DSA Clearance in Sensitized Patients
V. Fleetwood, D. Aufhauser, C. Papageorge, K. Janek, L. Hidalgo, B. Welch, R. Redfield, J. Mezrich
Department of Transplantation, University of Wisconsin, Madison, WI
*Purpose: The liver allograft clears class I donor specific antibody (DSA) more effectively than class II DSA. Persistent class II DSA in simultaneous liver kidney…
2020 American Transplant Congress
Acute Rejection in Liver Transplant Recipients is a Rising Predictor of Death and Graft Failure in the Recent Era of Declining Hepatitis C Virus
T. Bittermann¹, D. S. Goldberg², J. Levitsky³
¹University of Pennsylvania, Philadelphia, PA, ²University of Miami, Miami, FL, ³Northwestern University, Chicago, IL
*Purpose: Prior to 2013, hepatitis C virus (HCV) played a major role in liver transplant (LT) outcomes, and acute rejection (AR) was found to be…
2020 American Transplant Congress
Development of DSA Class II is Associated with Immunosuppressive Monotherapy and Increased Risk for Graft Fibrosis, Chronic Rejection and Graft Loss
M. Sterneck¹, B. Sultani¹, A. Ozga², S. Weidemann³, J. Hermann⁴, E. Grabhorn⁵, U. Herden⁶, L. Fischer⁶
¹University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²Insitute of Medical Biometry, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁴Pediatric Radiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁵Pediatric Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁶Transplant Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: Recent studies have suggested a negative impact of class 2 DSA on short term outcome of OLT recipients. The aim of this study was…
2020 American Transplant Congress
Liver Transplant Recipients with High DSA at Time of Transplant Do Not Have Increased Rejection or Mortality
A. Demirag¹, B. Rawashdeh¹, S. L. Lennon¹, S. Pelletier¹, J. Iezzoni², K. Khutsisvhili³, S. Shumilina¹, K. Chittum¹, J. Oberholzer¹, P. Lobo⁴
¹Department of Surgery, University of Virginia Medical Cener, Charlottesville, VA, ²Department of Pathology, University of Virginia Medical Cener, Charlottesville, VA, ³Histocompatibility Laboratory, University of Virginia Medical Cener, Charlottesville, VA, ⁴Department of Medicine, University of Virginia Medical Cener, Charlottesville, VA
*Purpose: Currently, there is controversy regarding transplanting livers in setting of high HLA-class ll DSA especially since prior studies demonstrated enhanced acute rejections in this…
2020 American Transplant Congress
De Novo NAFLD Post-Liver Transplant is Defined by Altered Lipid Metabolism and Mitochondrial Dysfunction
M. Bhat¹, E. Pasini¹, M. Angeli¹, J. Allard², A. Humar¹
¹Multi-Organ Transplant, UHN, Toronto, ON, Canada, ²Division of Gastroenterology and Hepatology, UHN, Toronto, ON, Canada
*Purpose: De Novo Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 35% of liver transplant (LT) recipients transplanted for non-NAFLD indications. Non-alcoholic steatohepatitis (NASH), the…